Fellowship for David Hilko (Griffith Uni)

Congratulations to Centre Affiliate Dr David Hilko (Griffith Uni) on the award of a Bridge and BridgeTech Industry Fellowship Placement through the MTPConnect QUT (Queensland University of Technology) David will work on site with GRIDD’s industry partner A/Prof Rakesh N. Veedu founder of SynGenis, a Western Australian based company that works in the exciting oligonucleotide research space.

The Bridge and BridgeTech Industry Fellowship Placement

The Bridge and BridgeTech Industry Fellowships, facilitated by QUT and funded by MTPConnect’s Researcher Exchange and Development within Industry (REDI) initiative for the Australian Government’s Medical Research Future Fund, provide up to $10,000 to support the placement of participants and alumni of the Bridge Program and BridgeTech Program within industry. More on the program can be found here.

CFBD CI receives funding for cystic fibrosis research

CFBD CI Professor Ray Norton has been awarded a grant worth $49,000 from the Monash Health Foundation 65 km Walk for Cystic Fibrosis Research Funding for his project entitled “Validating a potential new target for the treatment of cystic fibrosis”.

Ray’s project seeks to determine whether the protein channel KV1.3 plays a role in airway inflammation in individuals with cystic fibrosis [CF]. Ray and his team will examine broncho-alveolar lavage [BAL] fluid obtained from both young children with CF and adults with CF following lung transplantation.

Previous research has shown that KV1.3 is involved in other inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, but it is unknown if it is also important in CF lung disease or rejection in CF lung transplant recipients.

Lung inflammatory cells from BAL fluid will be tested for the presence of the KV1.3 channel. The group will also analyse BAL fluid from adults with CF post lung transplant, who will be having BAL as part of their routine post-transplant care at the Alfred Hospital Lung Transplant Service. We expect to find that KV1.3 is abundantly present in airway inflammatory cells in both patient groups.

If KV1.3 is detected, the next step will be to test whether blocking this channel with HsTX1[R14A], a novel peptide developed at Monash University, reduces inflammation and lung damage in animal models of CF lung disease and chronic rejection.

ARC Discovery Project Success

Congratulations to CFBD CI Professor Sally-Ann Poulsen from Griffith University for being awarded an ARC Discovery Project grant worth $415,495 together with Professor Katherine Andrews (Griffith Institute for Drug Discovery, Sciences). The project Chemical probes to dissect the cell cycle of globally important parasites aims to develop new reagents, called chemical probes, to visualise key biological events in globally important pathogens. The team will use innovative chemistry to modify the building blocks of DNA and provide researchers with essential tools to ‘see’ DNA synthesis in order to study growth and replication of pathogens in combination with microscopy. This project expects to support a major technical advance that will address important gaps in our understanding of many pathogens (e.g. those that cause malaria and tuberculosis), at both the cellular and molecular levels. This should provide significant benefits by enabling researchers worldwide to identify new intervention opportunities that target unique aspects of pathogen biology (with Dr Martin Blume, Robert Koch Institute).

Faculty Research Award for CI Professor Jonathan Baell

Congratulations to CFBD CI Professor Jonathan Baell for being awarded the Faculty Research Award from the Monash Institute of Pharmaceutical Sciences.

Jonathan discovers new medicines for treating diseases with unmet medical needs with a particular focus on cancer and infectious diseases. His track record is hallmarked by high-quality research outcomes in a variety of different areas, as exemplified by a broad and diverse suite of personally driven but widely collaborative patents integrated with subsequent high-quality publications.

With more than 70 granted patents, throughout his career Jonathan has been a driving force in facilitating commercial outcomes from academic research. At any given time, he incubates a variety of enterprising projects to maximise the chances of multiple translational outputs.

He is also the Director of the Australian Translational Medicinal Chemistry Facility (ATMCF), located at MIPS and which works with researchers nationwide in order to translate biomedical research outcomes. The Facility has secured over $7M in funding to enable the de-risking of projects through medicinal chemistry optimisation. In addition to the enterprise embodied in the ATMCF, Jonathan’s own patented KAT6A anticancer drug candidates have catalysed a global focus by Pharma on KATs as druggable targets. This innovative KAT6A work also has underpinned several awards, including Australia’s highest medicinal chemistry award, the Adrien Albert Award for Sustained Excellence in Medicinal Chemistry (2018), the Monash University Research Award for the Faculty of Pharmacy and Pharmacology (2019), the Scientific Achievement Award in Drug Discovery and Development (2020), awarded by the American Society for Pharmacology and Experimental Therapeutics, and in 2021 The Australian Academy of Technology and Engineering (ATSE) Clunies Ross Award for Knowledge Commercialisation.

Grant Success! CFBD CI Professor Joel Mackay to receive NHMRC Ideas Grant

Congratulations to CFBD CI Professor Joel Mackay from Sydney University who received an NHMRC Ideas Grant worth $829, 494.

New approaches to cancer treatment through mRNA display

This project will pioneer the development of a new class of molecules – cyclic peptides – that will block the activity of proteins that regulate gene expression and have been shown to be promising targets for a range of diseases, predominantly cancer. These molecules have the potential to be much more selective and potent than existing molecules and to also open up new directions for cancer therapy by allowing previously intractable molecular targets to be addressed.